Showing results (241-250 of 322) with videos related to
Sort By:
Pageof 33
Research Involvement and Engagement|July 2, 2025
Patient and public involvement in the SPRUCE methodology study investigating electronic patient reported outcomes in oncology clinical trialsMorgaine Stiles, Monisha Dewan, Georgina Manning, et al.British Journal of Cancer|October 21, 2021
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penisSteve Nicholson, Holly Tovey, Tony Elliott, et al.European Urology|October 4, 2018
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)John D Kelly, Wei Shen Tan, Nuria Porta, et al.European Urology Focus|July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyDavid Lorente, Praful Ravi, Niven Mehra, et al.Frontiers in Oncology|August 12, 2025
Radiation-induced extracellular matrix remodelling drives prognosis and predicts radiotherapy response in muscle-invasive bladder cancerConrado Guerrero Quiles, Siobhan Fahy, Matej Bartak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2024
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT TrialAlison Jane Birtle, Robert Jones, John Chester, et al.The Lancet. Oncology|July 9, 2023
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trialChristopher Nutting, Laura Finneran, Justin Roe, et al.Clinical and Translational Radiation Oncology|March 5, 2024
MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM studyKobika Sritharan, Lois Daamen, Angela Pathmanathan, et al.European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.British Journal of Cancer|April 13, 2016
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicityMahbubl Ahmed, Leila Dorling, Sarah Kerns, et al.Pageof 33